KR100327762B1 - 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 - Google Patents
짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 Download PDFInfo
- Publication number
- KR100327762B1 KR100327762B1 KR1020000003489A KR20000003489A KR100327762B1 KR 100327762 B1 KR100327762 B1 KR 100327762B1 KR 1020000003489 A KR1020000003489 A KR 1020000003489A KR 20000003489 A KR20000003489 A KR 20000003489A KR 100327762 B1 KR100327762 B1 KR 100327762B1
- Authority
- KR
- South Korea
- Prior art keywords
- hepatitis
- extract
- virus
- water
- straw
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 38
- 108091007433 antigens Proteins 0.000 title claims abstract description 38
- 102000036639 antigens Human genes 0.000 title claims abstract description 38
- 241001278836 Agrimonia pilosa Species 0.000 title claims abstract description 15
- 235000000641 Agrimonia pilosa Nutrition 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 title claims description 47
- 238000000034 method Methods 0.000 title claims description 5
- 230000002401 inhibitory effect Effects 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 208000006454 hepatitis Diseases 0.000 claims abstract description 12
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012153 distilled water Substances 0.000 claims abstract description 11
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 7
- 201000007270 liver cancer Diseases 0.000 claims abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000010902 straw Substances 0.000 claims description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 241000219422 Urtica Species 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 240000003291 Armoracia rusticana Species 0.000 claims description 5
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 5
- 235000009108 Urtica dioica Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000012223 aqueous fraction Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011356 non-aqueous organic solvent Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 241000801118 Lepidium Species 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 239000013049 sediment Substances 0.000 abstract description 2
- 229920002472 Starch Polymers 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 239000003021 water soluble solvent Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 102000003992 Peroxidases Human genes 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101710142246 External core antigen Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- -1 lamivudine Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- YGSFNCRAZOCNDJ-UHFFFAOYSA-N propan-2-one Chemical compound CC(C)=O.CC(C)=O YGSFNCRAZOCNDJ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Time | GOT | GPT | GTP | HBeAg | HBsAg |
95.3.17 | 222 | 388 | 111 | positive | + |
0.5 month | 151 | 311 | 119 | positive | + |
0.7 month | 118 | 239 | 108 | negative | + |
1.7 month | 44 | 75 | negative | + | |
2.0 month | 38 | 49 | negative | + | |
2.5 month | 37 | 49 | 32 | negative | + |
13.0 month | 26 | 40 | 40 | negative | + |
15.8 month | 23 | 24 | negative | + | |
19.7 month | 16 | 17 | negative | + | |
25.7 month | 20 | 15 | negative | + | |
현 재 | - | - | - | negative | + |
[주] : 서기돈, 주민등록번호 560915-1051125Date : 95YNation : R.O.KoreaSex : MaleAge : 40Diagnosis : Chronic HBV(활동성) |
Claims (8)
- B형 간염바이러스의 표면항원 생성억제능이 있는 천연식물 짚신나물 (Agrimonia pilosa L.)로부터 분리한 짚신나물 추출물.
- 짚신나물(Agrimonia pilosa L.)의 전초를 건조시킨 후 분쇄한 분쇄물을 증류수에 혼합하고 추출용액과 동량의 클로르포름을 반응시킨 다음 클로르포름 용해분획과 수용성 분획으로 분리한 다음 수용성 분획을 동량의 알콜로 추출하여 침전물을 얻는 것을 특징으로 하는 짚신나물 추출물의 제조방법.
- 짚신나물(Agrimonia pilosa L.)의 전초를 건조시킨 후 분쇄한 분쇄물을 증류수에 혼합하고 추출용액과 동량의 클로르포름을 반응시킨 다음 클로르포름 용해분획과 수용성 분획으로 분리한 다음 수용성 분획을 동량의 케톤계 유기용매로 추출하여 침전물을 얻는 것을 특징으로 하는 짚신나물 추출물의 제조방법.
- 짚신나물(Agrimonia pilosa L.)의 전초를 건조시킨 후 분쇄한 분쇄물을 증류수에 혼합하고 추출용액과 동량의 비수용성 유기용매를 반응시킨 다음 클로르포름용해분획과 수용성 분획으로 분리한 다음 수용성 분획을 동량의 디 메틸 포마미드 등의 수용성 유기용매로 추출하여 침전물을 얻는 것을 특징으로 하는 짚신나물 추출물의 제조방법.
- 짚신나물(Agrimonia pilosa L.)의 전초를 건조시킨 후 분쇄한 분쇄물을 증류수에 혼합하고 추출용액과 동량의 알콜을 반응시킨 다음 원심분리하여 침전물을 얻는 것을 특징으로 하는 짚신나물 추출물의 제조방법.
- 짚신나물(Agrimonia pilosa L.), 다닥냉이(Lepidium aspatum L.), 쐐기풀(Urtica dioca L.)의 전초를 건조시킨 후 분쇄한 분쇄물을 증류수에 혼합하여 얻은 추출용액과 동량의 비수용성 유기용매를 처리하고 유기용매 용해분획과 수용성 분획으로 분리한 다음 수용성 분획을 얻는 것을 특징으로 하는 짚신나물 추출물의 제조방법.
- 제2항, 제3항, 제4항, 제5항 및 제6항에 기재된 어느 하나의 방법에 의하여 제조된 추출물을 유효성분으로 하는 B형 간염 바이러스 감염에 의해 유발된 간염 및/또는 간암 등 간질환 치료제 조성물.
- 제2항, 제3항, 제4항, 제5항 및 제6항에 기재된 추출물을 유효성분으로 하는 식품 및/또는 식품첨가제 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000003489A KR100327762B1 (ko) | 2000-01-25 | 2000-01-25 | 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000003489A KR100327762B1 (ko) | 2000-01-25 | 2000-01-25 | 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010076077A KR20010076077A (ko) | 2001-08-11 |
KR100327762B1 true KR100327762B1 (ko) | 2002-03-15 |
Family
ID=19641314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000003489A KR100327762B1 (ko) | 2000-01-25 | 2000-01-25 | 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100327762B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021095921A1 (ko) | 2019-11-13 | 2021-05-20 | 주식회사 비티씨 | 아그리모니 추출물의 제조방법 및 그 추출물을 포함하는 간기능 개선용 또는 간질환 치료용 조성물 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010099494A (ko) * | 2001-10-09 | 2001-11-09 | 이영성, 권두한 | 큰등골짚신나물로부터 분리한 b형 간염바이러스 표면항원억제물질과 그 추출방법 및 용도 |
KR100525339B1 (ko) * | 2002-06-29 | 2005-11-02 | 바이오코리아 주식회사 | (e)-1-[[(2e,4e)-1-헥실-2,4-옥타데카디에닐]옥시]-2-하이드록시디아진 화합물 및 이를 포함하는 간염 치료제조성물 |
KR20070089434A (ko) * | 2006-02-28 | 2007-08-31 | 바이오코리아 주식회사 | 용아초속 식물 추출물을 함유하는 비 바이러스성 간염 또는간 질환의 치료 또는 예방용 약제학적 조성물 및 식품조성물 |
KR100763035B1 (ko) * | 2006-03-02 | 2007-10-04 | 주식회사 래디안 | 선학초로부터 여드름 개선 유효성분물질의 추출분리방법과이로부터 얻어지는 유효성분물질을 포함하는 화장료 조성물 |
KR101899122B1 (ko) * | 2017-04-20 | 2018-09-21 | 주식회사 제넨셀 | C형 간염 바이러스 감염 질환의 예방 또는 치료용 약학 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60255727A (ja) * | 1984-05-30 | 1985-12-17 | Riyouzou Koshiura | 制癌剤 |
JPS646289A (en) * | 1987-06-29 | 1989-01-10 | Lead Chem Co Ltd | Pharmaceutical composition for remedy and crisis-prevention of acquired immunodeficiency syndrome |
JPH0753398A (ja) * | 1993-08-11 | 1995-02-28 | Nippon Flour Mills Co Ltd | グルコシルトランスフェラーゼ阻害剤 |
KR950013517A (ko) * | 1993-11-22 | 1995-06-15 | 박태성 | 종양치료제 조성물 |
CN1197670A (zh) * | 1998-05-20 | 1998-11-04 | 靳家富 | 溃疡药物 |
JPH11180879A (ja) * | 1997-09-22 | 1999-07-06 | L'oreal Sa | バラ科植物エキスの用途 |
-
2000
- 2000-01-25 KR KR1020000003489A patent/KR100327762B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60255727A (ja) * | 1984-05-30 | 1985-12-17 | Riyouzou Koshiura | 制癌剤 |
JPS646289A (en) * | 1987-06-29 | 1989-01-10 | Lead Chem Co Ltd | Pharmaceutical composition for remedy and crisis-prevention of acquired immunodeficiency syndrome |
JPH0753398A (ja) * | 1993-08-11 | 1995-02-28 | Nippon Flour Mills Co Ltd | グルコシルトランスフェラーゼ阻害剤 |
KR950013517A (ko) * | 1993-11-22 | 1995-06-15 | 박태성 | 종양치료제 조성물 |
JPH11180879A (ja) * | 1997-09-22 | 1999-07-06 | L'oreal Sa | バラ科植物エキスの用途 |
CN1197670A (zh) * | 1998-05-20 | 1998-11-04 | 靳家富 | 溃疡药物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021095921A1 (ko) | 2019-11-13 | 2021-05-20 | 주식회사 비티씨 | 아그리모니 추출물의 제조방법 및 그 추출물을 포함하는 간기능 개선용 또는 간질환 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20010076077A (ko) | 2001-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chang et al. | Ethanol extract of Polygonum cuspidatum inhibits hepatitis B virus in a stable HBV-producing cell line | |
Gonçalves et al. | In vitro anti-rotavirus activity of some medicinal plants used in Brazil against diarrhea | |
CN105770207B (zh) | 紫花地丁提取物及其用途 | |
CN106727482B (zh) | 1,8-二己酰大黄素在制备抗hiv-1药物中的应用 | |
CN111150755B (zh) | 具有防治病毒性疾病的中药组合物及其应用 | |
KR100327762B1 (ko) | 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 | |
KR100988877B1 (ko) | 작약 추출물을 유효성분으로 하는 b형 간염 치료제 조성물 | |
CN101695511B (zh) | 石榴皮提取物及其生产方法和应用 | |
KR100557015B1 (ko) | 개선된 항 b형 간염바이러스 활성을 갖는 짚신나물추출물을 제조하는 방법 및 그러한 추출물을 함유한약제학적 조성물 또는 식품 조성물 | |
CN102724990A (zh) | 药用植物的提取物及其应用 | |
JP3249136B2 (ja) | フィラントゥス ウスリエンシスおよび/またはフィラントゥス ウリナリアの抽出物を含むb型肝炎治療用医薬組成物 | |
KR100351755B1 (ko) | 다닥냉이로부터 분리한 b형 간염바이러스 표면항원 생성억제 추출물 및 그 분리방법 | |
CN1989989B (zh) | 六棱菊属植物提取物在制备抑制单纯疱疹病毒及乙肝病毒的药物组合物中的用途 | |
CN112618584A (zh) | 四块瓦提取物在制备抗乙型肝炎病毒和/或防治乙型肝炎的药物中的应用 | |
CN111743935A (zh) | 防治登革热病毒的中药组合物及其制备方法 | |
CN110840969B (zh) | 一种治疗丙型肝炎的中药组合物及其应用 | |
RU2072865C1 (ru) | Способ получения вещества, обладающего противовирусной и иммуностимулирующей активностью | |
KR100332485B1 (ko) | 마황 추출물을 유효성분으로 하는 b형 간염 치료제 | |
CN117982563A (zh) | 一种中药组合物在制备抗登革病毒药物中的应用 | |
Yeh et al. | Downregulation of hepatitis B surface antigen expression in human hepatocellular carcinoma cell lines by HD‐03, a polyherbal formulation | |
KR100331174B1 (ko) | 정향 추출물을 유효성분으로 하는 b형 간염 치료제 | |
CN113230289A (zh) | 桑黄和百蕊草复方作为新型冠状病毒治疗药物或抗病毒制剂的用途 | |
KR100351756B1 (ko) | 식물로부터분리한신규한간암세포괴사물질과그분리방법및용도 | |
CN105748546A (zh) | 墨旱莲提取物在制备抗骨质疏松多靶点药物或保健品中的应用 | |
CN113230288A (zh) | 百蕊草或百蕊草提取物或百蕊草萃取物作为新型冠状病毒治疗药物或抗病毒制剂用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130823 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140324 Year of fee payment: 13 |
|
G170 | Re-publication after modification of scope of protection [patent] | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20160225 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20170425 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20180723 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 18 |